Table 1.

4NQO-Induced Tumorigenesis in p53 Transgenic (p53Val135/WT) Mice

GroupGenotypenTreatment*Tumor incidence (%)
Tumor multiplicity
Oral cavityEsophagusForestomach/stomachOral cavityEsophagus
1p53WT/WT12Vehicle00/12 (0)0/12 (0)00
2p53Val135/WT12Vehicle00/12 (0)0/12 (0)00
3p53WT/WT244NQO6/24 (25.0)14/24 (58.3)1/24 (4.2)0.3 ± 0.51.0 ± 1.0
4p53Val135/WT244NQO16/24 (66.7)22/24 (91.7)5/24 (20.8)1.0 ± 0.93.2 ± 2.0
  • * Approximately equal numbers of males and females were used, with no significant difference in tumor multiplicity between the sexes. At age 6 weeks, mice in groups 1 and 2 were given vehicle. Mice in groups 3 and 4 were given 4NQO (5 mg/mL in propylene glycol) thrice weekly for 16 weeks. All animals were terminated 32 weeks after last dose 4NQO treatment.

  • P < 0.05, tumor incidence in p53Val135/WT mice (group 4) was significantly different from that of p53WT/WT mice (group 3; Fisher's exact test).

  • P < 0.001, tumor multiplicity in p53Val135/WT mice (group 4) was significantly different from that of p53WT/WT mice (group 3; Wilcoxon's rank-sum test).